US Bancorp DE Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

US Bancorp DE boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 2,432.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,887 shares of the company’s stock after acquiring an additional 6,615 shares during the quarter. US Bancorp DE’s holdings in Arcus Biosciences were worth $103,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. FMR LLC raised its position in Arcus Biosciences by 6.9% during the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock valued at $68,309,000 after acquiring an additional 286,766 shares in the last quarter. Point72 Asset Management L.P. raised its position in Arcus Biosciences by 32.9% during the third quarter. Point72 Asset Management L.P. now owns 2,437,073 shares of the company’s stock valued at $37,263,000 after acquiring an additional 603,222 shares in the last quarter. Parkman Healthcare Partners LLC raised its position in Arcus Biosciences by 146.9% during the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock valued at $15,684,000 after acquiring an additional 610,219 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after acquiring an additional 186,750 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock valued at $8,669,000 after buying an additional 59,536 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Stock Down 2.0 %

NYSE RCUS opened at $9.35 on Monday. The business has a fifty day moving average price of $12.25 and a 200 day moving average price of $14.87. Arcus Biosciences, Inc. has a one year low of $9.01 and a one year high of $19.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The company has a market cap of $982.51 million, a P/E ratio of -2.97 and a beta of 1.36.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on RCUS shares. HC Wainwright upgraded Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Bank of America cut their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Finally, Morgan Stanley cut their price objective on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $30.25.

Insider Activity at Arcus Biosciences

In related news, CEO Terry J. Rosen bought 19,800 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $10.06 per share, with a total value of $201,200.00. Following the completion of the acquisition, the director now owns 28,400 shares in the company, valued at $285,704. This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.